Welcome to our dedicated page for Medexus Pharmace news (Ticker: MEDXF), a resource for investors and traders seeking the latest updates and insights on Medexus Pharmace stock.
Medexus Pharms Inc (MEDXF), referred to in its disclosures as Medexus Pharmaceuticals, generates a steady flow of news related to its specialty pharmaceutical business in North America. Investors following MEDXF news can see updates on hematology and hematology-oncology products, as well as allergy, dermatology, and rheumatology therapies that form the company’s core portfolio.
Many Medexus news releases focus on GRAFAPEX (treosulfan) for Injection, an alkylating agent used as part of a preparative regimen for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndrome. The company reports on FDA approval, Orphan Drug Designation, US commercial launch timing, and key reimbursement milestones such as CMS New Technology Add-On Payment (NTAP) approval, transitional pass-through status, and assignment of a permanent HCPCS Level II "J code". These items provide insight into how Medexus is building its hematology-oncology franchise in the United States.
MEDXF news also covers quarterly and annual financial results, including net revenue, net income, Adjusted EBITDA, and product-level performance for GRAFAPEX, Trecondyv, IXINITY, Rupall, Rasuvo, Metoject, and Gleolan. The company uses these releases to discuss unit demand trends, the impact of generic competition on products such as Rupall, and portfolio dynamics across the United States and Canada.
Additional news topics include financing and capital allocation decisions, such as new senior secured credit facilities with National Bank of Canada, repayment of prior credit agreements, and the launch or renewal of a normal course issuer bid (NCIB) for Medexus common shares on the Toronto Stock Exchange. Governance-related items, including annual meetings of shareholders, director elections, and auditor appointments, are also reported.
For anyone tracking MEDXF, this news stream offers detailed information on product launches, regulatory and reimbursement milestones, financial performance, credit arrangements, and share repurchase activity. Bookmarking the Medexus news feed on Stock Titan can help investors and researchers follow how the company’s North American specialty pharmaceutical platform evolves over time.
Medexus Pharmaceuticals Inc. (TSXV: MDP, OTCQX: MEDXF) will host a conference call on June 17, 2021, at 8:00 AM ET to discuss its financial results for the fiscal year ended March 31, 2021. Financial statements and MD&A will be filed post-market on June 16, 2021. The call can be accessed via telephone or through a webcast. Medexus focuses on innovative rare disease treatments, including Rasuvo™, IXINITY®, and Rupall®, and aims to advance its portfolio to support growth over the next decade.
Medexus Pharmaceuticals has expanded its medical affairs team in anticipation of launching treosulfan, an innovative agent for patients receiving allo-HSCT. This proactive measure aims to ensure a successful launch by the scheduled PDUFA date in August 2021. Treosulfan, which showed a 64.0% two-year event-free survival rate in clinical trials, is projected to become the new standard of care, filling a significant market gap. The team includes experienced leaders like Keith Steward and J. Lynn Bass, enhancing Medexus's capability to engage with key stakeholders.
Medexus Pharmaceuticals (MEDXF) has announced the immediate availability of Triamcinolone Hexacetonide (TH) Injectable Suspension in the U.S. through the FDA’s Drug Shortage program. This drug is indicated for treating various inflammatory joint diseases. Medexus is collaborating with Ethypharm to expedite the data necessary for filing an Abbreviated New Drug Application (ANDA). The company aims to establish a solid portfolio in rare diseases, focusing on innovative healthcare products and expanding its commercial presence across North America.
Medexus Pharmaceuticals, listed as OTCQX: MEDXF, announced their participation in the LD Micro Invitational XI investor conference from June 8-10, 2021. CEO Ken d’Entremont and CFO Roland Boivin will present on June 8 at 12:30 p.m. EST. The conference provides a platform for investors to gain insights into Medexus's growth strategy in the rare disease market. Medexus focuses on innovative therapies for auto-immune diseases, hematology, and allergies, with prominent products like Rasuvo™, IXINITY®, and Rupall®.
Medexus Pharmaceuticals announced its participation in the Sidoti & Company Virtual Microcap Conference from May 19 to May 20, 2021. CEO Ken d’Entremont and CFO Roland Boivin will present on May 19 at 9:15 AM Eastern Time, with a live webcast available for replay. The company will also hold one-on-one virtual meetings with interested investors. Medexus focuses on innovative and rare disease treatments, particularly in auto-immune disease, hematology, and allergy, featuring products like Rasuvo™ and IXINITY®.
Medexus Pharmaceuticals announced participation in upcoming investor conferences, including the Bloom Burton & Co. Healthcare Investor Conference on April 20, 2021, and the Stifel 2021 Canada Cross Sector Insight Conference on April 21, 2021. CEO Ken d’Entremont and CFO Roland Boivin will present corporate updates to engage with investors. Medexus focuses on innovative treatments for rare diseases, providing products like Rasuvo™ and IXINITY® for auto-immune diseases and hemophilia. The company aims to enhance its market presence and investor relationships through these events.
Medexus Pharmaceuticals has announced that all non-executive directors will receive restricted share units (RSUs) instead of cash fees for 2021. This decision aligns with the Company’s 2018 omnibus equity incentive plan. The RSUs will vest immediately, allowing directors to acquire common shares at $0.01 each. Medexus focuses on developing innovative products for rare diseases, particularly in auto-immune diseases and hematology, with notable products like Rasuvo™ and IXINITY®. The Company's strategic move to offer RSUs may enhance alignment with shareholder interests.
Medexus Pharmaceuticals Inc. (OTCQX: MEDXF) announced that CEO Ken d’Entremont and CFO Roland Boivin will hold 1x1 meetings with investors at the 33rd Annual Roth Conference from March 15-17, 2021. This virtual event includes small group meetings, analyst-led fireside chats, and on-demand company presentations. Medexus focuses on innovative treatments for rare diseases, including Rasuvo™ for rheumatoid arthritis, IXINITY® for Hemophilia B, and Rupall® for allergies. The company aims to provide high-quality healthcare products through its core values.
Medexus Pharmaceuticals reported record fiscal third-quarter revenue of $31.5 million for the three months ending December 31, 2020, a 94% increase from $16.2 million year-over-year. Adjusted EBITDA rose to $5.1 million from $0.7 million. Despite this revenue growth, the company experienced a net loss of $17.1 million, attributed primarily to a significant increase in the fair value of derivative instruments. The company completed a $32.5 million financing and acquired licensing rights for treosulfan, aiming to boost future growth.
Medexus Pharmaceuticals announced the commercial launch of Gleolan® in Canada, an imaging agent for brain tumor surgery, previously available only through the Health Canada Special Access Program. Gleolan enhances visualization of malignant tissue during surgery for Grades III and IV gliomas, significantly increasing complete tumor resection rates. A pivotal Phase III study showed 65% complete resection with Gleolan versus 36% without, and 41% of patients were progression-free after six months. The launch aims to improve surgical outcomes for the 1,000 Canadians diagnosed with glioblastoma annually.